| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1041: Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer |
|
Medicine details |
|
| Medicine name | durvalumab (Imfinzi®) |
| Formulation | Infusion |
| Reference number | 4136 |
| Indication | In combination with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 20/12/24 |
| NICE guidance | |